FR2264531A1 - - Google Patents

Info

Publication number
FR2264531A1
FR2264531A1 FR7508701A FR7508701A FR2264531A1 FR 2264531 A1 FR2264531 A1 FR 2264531A1 FR 7508701 A FR7508701 A FR 7508701A FR 7508701 A FR7508701 A FR 7508701A FR 2264531 A1 FR2264531 A1 FR 2264531A1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7508701A
Other languages
French (fr)
Other versions
FR2264531B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Publication of FR2264531A1 publication Critical patent/FR2264531A1/fr
Application granted granted Critical
Publication of FR2264531B1 publication Critical patent/FR2264531B1/fr
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
    • C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/575—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
FR7508701A 1974-03-20 1975-03-20 Expired FR2264531B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2413935A DE2413935A1 (de) 1974-03-20 1974-03-20 4-(polyalkoxy-phenyl)-2-pyrrolidone

Publications (2)

Publication Number Publication Date
FR2264531A1 true FR2264531A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1975-10-17
FR2264531B1 FR2264531B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1978-07-28

Family

ID=5910915

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7508701A Expired FR2264531B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1974-03-20 1975-03-20

Country Status (20)

Country Link
US (1) US4012495A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPS6011028B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) AT347931B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE826923A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1069517A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH (1) CH621338A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CS (1) CS214738B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DD (1) DD119229A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE2413935A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK139965C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES435750A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR2264531B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB1498705A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU174074B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE40865B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL46883A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL7503367A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SE (1) SE402010B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SU (1) SU649312A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
YU (1) YU40258B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0671389A1 (en) * 1994-03-08 1995-09-13 Mitsubishi Chemical Corporation 3-Phenylpyrrolidine derivatives
WO2004094375A3 (en) * 2003-04-16 2005-04-21 Memory Pharm Corp 4 - (3,4 - disubstituted phenyl) - pyrrolidin-2-one compounds as phosphodiesterase 4 inhibitors
US7235579B2 (en) 2001-10-16 2007-06-26 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4193926A (en) 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
DE2541855A1 (de) * 1975-09-18 1977-03-31 Schering Ag 4-(polyalkoxy-phenyl)-2-pyrrolidone ii
CU21107A3 (es) 1978-02-10 1988-02-01 Hoffmann La Roche Pyrrolidines derivatives
IL57266A (en) * 1978-06-12 1982-12-31 Mundipharma Ag Production of pyrrolidin-2-ones and of 3-pyrrolin-2-ones
IT1131959B (it) * 1979-08-09 1986-06-25 Hoffmann La Roche Derivati pirrolidinici
GB2123288A (en) * 1982-07-16 1984-02-01 Wellcome Found Anti-thrombotic agent
US4584313A (en) * 1984-05-07 1986-04-22 Warner-Lambert Company (Substituted-phenyl)-5-oxo-2-pyrrolidinepropanoic acids and esters thereof, and use for reversing electroconvulsive shock-induced amnesia
US4548947A (en) * 1984-05-07 1985-10-22 Warner-Lambert Company 1-(Substituted-aryl)-dihydro-1H-pyrrolizine-3,5-[2H,6H-]diones and use for reversing amnesia
DE3438839A1 (de) * 1984-10-19 1986-04-24 Schering AG, 1000 Berlin und 4709 Bergkamen Pharmazeutische praeparate
US5783591A (en) * 1984-10-19 1998-07-21 Schering Aktiengesellschaft Administration of oxazolidinone and pyrolidinone compounds for the treatment of inflammation
WO1987006576A1 (en) * 1986-04-29 1987-11-05 Pfizer Inc. Calcium independent camp phosphodiesterase inhibitor antidepressant
US5459145A (en) * 1988-01-19 1995-10-17 Pfizer Inc. Calcium independent camp phosphodiesterase inhibitor antidepressant
FI875101L (fi) * 1986-12-03 1988-06-04 Tanabe Seiyaku Co Laktamderivat och preparat innehaollande dessa.
US4971959A (en) * 1987-04-14 1990-11-20 Warner-Lambert Company Trisubstituted phenyl analogs having activity for congestive heart failure
US5274002A (en) * 1987-04-14 1993-12-28 Warner-Lambert Company Trisubstituted phenyl analogs having activity for congestive heart failure
US4960457A (en) * 1988-12-27 1990-10-02 Ici Americas Inc. Substituted 1,3-diphenyl pyrrolidones and their use as herbicides
DE3921593A1 (de) * 1989-06-28 1991-01-10 Schering Ag Verfahren zur racemattrennung von 4-aryl-2-oxo-pyrrolidin-3-carbonsaeure-ester
JP2578001B2 (ja) * 1989-12-11 1997-02-05 明治製菓株式会社 抗痴呆薬
DE3943385A1 (de) * 1989-12-27 1991-07-04 Schering Ag Mittel zur transdermalen applikation enthaltend rolipram
DD299058A5 (de) * 1990-01-31 1992-03-26 Arzneimittelwerk Dresden Gmbh,De Verfahren zur herstellung von n-acyl-4-phenyl-pyrrolidin-2-onen mit cerebroprotektiver wirkung
GB9009395D0 (en) * 1990-04-26 1990-06-20 Orion Yhtymae Oy Cyclic hydroxamic acids and their use
CA2088352A1 (en) * 1990-08-03 1992-02-04 Klaus M. Esser Tnf inhibitors
DE4032055A1 (de) * 1990-10-05 1992-04-09 Schering Ag Verfahren zur herstellung von optisch aktiven 4-aryl-2-pyrrolidinonen
US5547979A (en) * 1992-03-30 1996-08-20 Smithkline Beecham TNF inhibition
US5395935A (en) * 1992-05-08 1995-03-07 Pfizer Inc. Endo-bicyclo[2.2.1]heptan-2-ol and derived pharmaceutical agents
GB9212673D0 (en) * 1992-06-15 1992-07-29 Celltech Ltd Chemical compounds
GB9222253D0 (en) * 1992-10-23 1992-12-09 Celltech Ltd Chemical compounds
GB9226830D0 (en) * 1992-12-23 1993-02-17 Celltech Ltd Chemical compounds
US5622977A (en) * 1992-12-23 1997-04-22 Celltech Therapeutics Limited Tri-substituted (aryl or heteroaryl) derivatives and pharmaceutical compositions containing the same
GB9304920D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9304919D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9312853D0 (en) 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
US5665754A (en) * 1993-09-20 1997-09-09 Glaxo Wellcome Inc. Substituted pyrrolidines
US5477611A (en) * 1993-09-20 1995-12-26 Tessera, Inc. Method of forming interface between die and chip carrier
ATE260911T1 (de) * 1993-12-22 2004-03-15 Celltech R&D Ltd Trisubstituierte phenyl-derivate, verfahren zu deren herstellung und deren verwendung als phosphodiesterase (typ iv) hemmstoffe
GB9326173D0 (en) * 1993-12-22 1994-02-23 Celltech Ltd Chemical compounds and process
US5338739A (en) * 1994-03-10 1994-08-16 Hoechst-Roussel Pharmaceuticals Inc. (Pyrrolidinyl)phenyl carbamates, compositions and use
US5786354A (en) * 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
US6245774B1 (en) 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
GB9412571D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412573D0 (en) * 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412672D0 (en) * 1994-06-23 1994-08-10 Celltech Ltd Chemical compounds
US5591776A (en) 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
US5922751A (en) 1994-06-24 1999-07-13 Euro-Celtique, S.A. Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
US5665737B1 (en) * 1994-10-12 1999-02-16 Euro Celtique Sa Substituted benzoxazoles
JPH10508032A (ja) * 1994-12-13 1998-08-04 ユーロ−セルティーク，エス．エイ． アリールチオキサンチン類
US6025361A (en) 1994-12-13 2000-02-15 Euro-Celtique, S.A. Trisubstituted thioxanthines
AU706159B2 (en) * 1995-02-10 1999-06-10 Schering Aktiengesellschaft Pharmaceutical preparations for TNF inhibition
US6268373B1 (en) 1995-06-07 2001-07-31 Euro-Celtique S.A. Trisubstituted thioxanthines
US6166041A (en) 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
DE19540475A1 (de) * 1995-10-20 1997-04-24 Schering Ag Chirale Methylphenyloxazolidinone
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9526243D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526246D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526245D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
US6075016A (en) 1996-04-10 2000-06-13 Euro-Celtique S.A. 6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity
GB9608435D0 (en) * 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
US5864037A (en) 1996-06-06 1999-01-26 Euro-Celtique, S.A. Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity
JP4017214B2 (ja) 1996-06-11 2007-12-05 興和創薬株式会社 ５−フェニル−３−ピリダジノン誘導体
EP0928789B1 (en) 1996-07-31 2004-09-29 Nikken Chemicals Company, Limited 6-phenyltetrahydro-1,3-oxazin-2-one derivatives and medicinal compositions containing the same
EP0924204A4 (en) 1996-08-27 2002-10-23 Nikken Chemicals Co Ltd 2-PHENYLMORPHOLIN-5-ON DERIVATIVES AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME
GB9619284D0 (en) * 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
US5744473A (en) * 1996-09-16 1998-04-28 Euro-Celtique, S.A. PDE IV inhibitors: "bis-compounds"
GB9622363D0 (en) 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
GB9625184D0 (en) * 1996-12-04 1997-01-22 Celltech Therapeutics Ltd Chemical compounds
AU5330698A (en) * 1996-12-23 1998-07-17 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
GB9713087D0 (en) * 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
CA2295106C (en) 1997-06-24 2007-03-13 Nikken Chemicals Co., Ltd. 3-anilino-2-cycloalkenone derivatives
DE69824632T2 (de) 1997-11-12 2005-06-09 Mitsubishi Chemical Corp. Purinderivate und medikamente, welche dieselben als aktiven bestandteil enthalten
US7427606B2 (en) 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US6232297B1 (en) * 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
AU4319000A (en) * 1999-05-11 2000-11-21 Mitsubishi Chemical Corporation Purine derivative dihydrate, drugs containing the same as the active ingredient and intermediate in the production thereof
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
ES2260043T3 (es) 1999-08-21 2006-11-01 Altana Pharma Ag Combinacion sinergica de roflumilast y salmeterol.
GB9924862D0 (en) * 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
AU2001239550A1 (en) * 2000-03-23 2001-10-03 Takeda Chemical Industries Ltd. Furoisoquinoline derivatives, process for producing the same and use thereof
NZ529654A (en) * 2001-05-29 2005-12-23 Schering Ag CDK inhibiting pyrimidines, production thereof and their use as medicaments
ATE476173T1 (de) * 2001-07-16 2010-08-15 Merck Patent Gmbh Photostabile organische sonnenschutzmittel mit antioxidativen eigenschaften
JP4514452B2 (ja) * 2001-10-01 2010-07-28 ユニバーシティ オブ バージニア パテント ファウンデーション Ａ２ａアゴニスト活性を有する２−プロピルアデノシン・アナログおよびその組成物
US20090170803A1 (en) * 2002-04-10 2009-07-02 Linden Joel M Adjunctive treatment of biological diseases
US20060106048A1 (en) * 2002-07-26 2006-05-18 Yoshihisa Inoue Furoisoquinoline derivative and use thereof
AU2003285952A1 (en) * 2002-10-21 2004-05-13 Irm Llc Pyrrolidones with anti-hiv activity
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7153824B2 (en) 2003-04-01 2006-12-26 Applied Research Systems Ars Holding N.V. Inhibitors of phosphodiesterases in infertility
MXPA05011200A (es) * 2003-04-18 2005-12-14 Memory Pharm Corp Derivados de pirazol como inhibidores de fosfodiesterasa 4.
MXPA05011443A (es) * 2003-04-25 2006-05-31 Icos Corp Metodo de preparar un compuesto anular que tenga dos centros quirales adyancentes.
JP4925821B2 (ja) * 2004-05-17 2012-05-09 大塚製薬株式会社 チアゾール化合物及びその用途
WO2006023272A1 (en) 2004-08-02 2006-03-02 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having a2a agonist activity
WO2006015357A2 (en) 2004-08-02 2006-02-09 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
WO2006028618A1 (en) 2004-08-02 2006-03-16 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
EP1799673A1 (en) 2004-10-15 2007-06-27 Memory Pharmaceuticals Corporation Pyrazole derivatives as phosphodiesterase 4 inhibitors
WO2006044955A1 (en) * 2004-10-20 2006-04-27 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
WO2007120972A2 (en) * 2006-02-10 2007-10-25 University Of Virginia Patent Foundation Method to treat sickle cell disease
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
ES2393885T7 (es) 2007-06-04 2014-01-30 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US8058259B2 (en) 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2010075086A2 (en) * 2008-12-15 2010-07-01 Auspex Pharmaceuticals, Inc. Pyrrolidinone inhibitors of pde-4
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP3366698A1 (en) 2011-03-01 2018-08-29 Synergy Pharmaceuticals Inc. Guanylate cyclase c agonists
ES2395801B1 (es) 2011-06-23 2014-06-06 María Carmen PARDINA PALLEJÀ "pentoxifilina por vía transvaginal para el tratamiento de la infertilidad"
AU2014218599C1 (en) 2013-02-25 2018-09-06 Bausch Health Ireland Limited Guanylate cyclase receptor agonists for use in colonic cleansing
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
EA201592263A1 (ru) 2013-06-05 2016-05-31 Синерджи Фармасьютикалз, Инк. Ультрачистые агонисты гуанилатциклазы c, способ их получения и использования
KR102456567B1 (ko) 2013-08-09 2022-10-19 알데릭스, 인코포레이티드 인산염 수송을 억제하기 위한 화합물 및 방법
EP3972599A1 (en) 2019-05-21 2022-03-30 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1516776A (fr) 1966-07-21 1968-03-15 Rhone Poulenc Sa Nouveaux dérivés du pyrrole et leur préparation
GB1350582A (en) * 1970-07-24 1974-04-18 Ucb Sa Cerivatives of 2-pyrrolidinone

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0671389A1 (en) * 1994-03-08 1995-09-13 Mitsubishi Chemical Corporation 3-Phenylpyrrolidine derivatives
US5545647A (en) * 1994-03-08 1996-08-13 Mitsubishi Chemical Corporation 3-phenylpyrrolidine derivatives
US7235579B2 (en) 2001-10-16 2007-06-26 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
WO2004094375A3 (en) * 2003-04-16 2005-04-21 Memory Pharm Corp 4 - (3,4 - disubstituted phenyl) - pyrrolidin-2-one compounds as phosphodiesterase 4 inhibitors
US7696198B2 (en) 2003-04-16 2010-04-13 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors

Also Published As

Publication number Publication date
IL46883A (en) 1979-09-30
CH621338A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1981-01-30
IE40865L (en) 1975-09-20
SE402010B (sv) 1978-06-12
YU63275A (en) 1982-06-30
CS214738B2 (en) 1982-05-28
YU40258B (en) 1985-10-31
DE2413935C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1988-05-26
FR2264531B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1978-07-28
NL7503367A (nl) 1975-09-23
DK110675A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1975-09-21
DK139965B (da) 1979-05-28
DD119229A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1976-04-12
CA1069517A (en) 1980-01-08
SU649312A3 (ru) 1979-02-25
AT347931B (de) 1979-01-25
DE2413935A1 (de) 1975-10-16
IE40865B1 (en) 1979-08-29
JPS6011028B2 (ja) 1985-03-22
HU174074B (hu) 1979-10-28
DK139965C (da) 1979-10-29
IL46883A0 (en) 1975-05-22
BE826923A (fr) 1975-09-22
AU7931075A (en) 1976-09-23
ATA210975A (de) 1978-06-15
JPS50157360A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1975-12-19
SE7503157L (sv) 1975-11-28
US4012495A (en) 1977-03-15
GB1498705A (en) 1978-01-25
ES435750A1 (es) 1976-12-16

Similar Documents

Publication Publication Date Title
FR2264531B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI750815A7 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU495898B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR2261753B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR2260631B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE2537357C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU7205174A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CS171060B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU6599874A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU480578A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DD111155A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU481441A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BG19892A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU481001A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU481898A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DD120876A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU480922A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU480879A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DD118515A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU480701A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BG19962A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU479769A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU482208A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU479624A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DD115284A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)